
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana has increased its earnings per share (EPS) estimate for 2025 to $17.06, reflecting strong second-quarter results and revised guidance that indicate solid operational performance. The company's anticipated year-over-year earnings growth for 2027, driven by effective margin initiatives, reinforces optimism regarding its financial trajectory, despite challenges related to star ratings and bonus payments. Additionally, with an above-industry star rating profile in Medicare Advantage and successful environmental sustainability targets, Humana is uniquely positioned to adapt to regulatory changes while enhancing its competitive advantage.
Bears say
The outlook for Humana's stock is negatively impacted by expected declines in earnings per share (EPS) for 2026, primarily due to persistent challenges related to the company's Medicare Advantage (MA) program and competition in the market. Key downside risks include increased utilization of medical assistance, inadequate reimbursement rates, and declining Star ratings, which the company acknowledges could adversely affect the performance of its earnings. Furthermore, the anticipated need for increased investments to enhance Star program outcomes signals a potential strain on financial results, with projections indicating that FY27 EPS may fall approximately 10% short of earlier estimates.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares